What Korify Capital does

Korify Capital is a venture capital firm founded in 2020 and headquartered in Santa Venerina, Italy, that invests in Series A through C rounds of biotechnology companies with strong traction and validated proof of concept. The firm concentrates its thesis across three verticals — longevity, mental health, and regenerative medicine — and backs pioneering teams developing technologies such as AI-derived psychiatric biomarkers (Alto Neuroscience), FOXO modulators (Refoxy), proteasome activators (Booster Therapeutics), cellular reprogramming (Nula Therapeutics), and reproductive longevity platforms (Gameto). Its core intellectual contribution is the Distributed Development Companies (DisCos) framework, which builds infrastructure for multiple uncorrelated development programs to increase probability of portfolio success, alongside a domain-specialization investment approach emphasizing scalable, target-agnostic platform plays.

Korify Capital operates as the biotech-focused investment arm of the Infinitas Capital family office, founded by Robin Lauber. The investment vehicle is Infinitas SICAV Limited, a Notified Alternative Fund domiciled in Malta and managed by Altarius Asset Management Ltd, an Alternative Investment Fund Manager licensed and regulated by the Malta Financial Services Authority. Korify Capital itself is registered with the SEC as an Exempt Reporting Adviser, and Infinitas Investments Ltd serves as the appointed investment advisor. This structure gives the firm institutional-grade cross-border fund infrastructure spanning the USA, Switzerland, Germany, the Netherlands, the UK, Austria, and France.

The firm's revenue model is conventional for an early-stage VC: it deploys limited-partner capital into equity positions in portfolio companies and generates returns through capital appreciation and exits. Management fees and potential carried interest on Infinitas SICAV Limited are the primary revenue streams, but neither is publicly disclosed. Korify maintains a lean team of 1-10, co-led by founding partners Robin Lauber and Davide Ottolini (who previously consulted for big pharma at EY), and distributes its brand primarily through a corporate website, LinkedIn, and portfolio-company news amplification rather than active fundraising marketing.

Name

Korify Capital

Legal name

Infinitas Investments Ltd.

Website

https://korifycapital.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Korify Capital is a Malta-domiciled, Italy-based venture capital firm (founded 2020) investing Series A-C rounds into biotech companies in longevity, mental health, and regenerative medicine, operating as the biotech arm of the Infinitas Capital family office.

Ownership category

akta.pro rank

Product category

Venture Capital / Biotech Investment

NAICS

Portfolio Management and Investment Advice (523940), Other Investment Pools and Funds (5259), Other Financial Vehicles (525990)

SIC

Investment Advice (6282), Investors, Nec (6799)

akta.pro primary industry

SDG / Thematic Sustainable Investment Funds (FSANAJAN)

Keywords

• Venture capital investing
• Biotech venture funding
• Longevity investments
• Mental health investments
• Early-stage growth equity

Headquarters

HQ city

Santa Venerina

HQ country

Italy

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Investment Returns: As a venture capital firm, Korify Capital generates returns through equity investments in portfolio companies. Infinitas SICAV Limited is a Notified Alternative Fund managed by Altarius Asset Management Ltd. The firm is registered with the SEC as an Exempt Reporting Adviser.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Korify Capital is a venture capital firm that invests Series A to C equity rounds into privately held biotechnology companies with validated proof of concept, focusing on longevity, mental health, and regenerative medicine. The firm provides capital and strategic support to pioneering teams developing breakthrough therapeutics, applying a Distributed Development Companies (DisCo) approach that backs multiple uncorrelated development programs to diversify risk.

Product overview

Korify Capital operates as a venture capital investment firm offering a single unified investment platform focused on funding and supporting biotechnology companies. The firm backs breakthrough technologies in longevity, mental health, and regeneration through three core investment strategies: distributed development companies (DisCos), enabling technologies, and domain-specific platforms. Rather than a product-plus-modules architecture, the offering centers on providing capital and strategic guidance to portfolio companies, with investments ranging from Series A to Series C stages.

Differentiator

Problem solved

Functional benefit

Products and services

• Korify Capital Investment Services Venture capital investment platform providing Series A to C equity capital and strategic support to privately held biotechnology companies with validated proof of concept, focused on longevity, mental health, and regenerative medicine. Targeted at founders, CEOs, and boards of biotech companies seeking growth-stage capital and a specialized investor partner.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Khosla Ventures: Large multi-stage venture firm with significant biotech and healthspan allocation alongside consumer and tech. Overlaps with Korify in early-stage biotech conviction but with far larger AUM and broader sector mandate.
• ARCH Venture Partners: One of the largest and most established biotech-focused venture firms, with deep exposure to longevity and platform biotechs. Competes for similar Series A–C biotech allocations but at significantly larger fund sizes and broader scope.
• Andreessen Horowitz (Bio + Health): Major venture platform with dedicated bio/health fund deploying into early-stage biotech, mental health, and healthtech companies. Comparable in stage and thematic interest but materially larger in scale and team.
• Forbion: Leading European life sciences venture firm investing across Series A through late-stage biotech with therapeutic focus areas including longevity-adjacent indications. Comparable in European base and biotech concentration, but with substantially larger fund vehicles.

Direct peers

• Juvenescence: Longevity-focused biotech investment firm building and funding companies developing therapies to extend healthy human lifespan. Direct peer to Korify given overlapping thesis across aging biology, cellular reprogramming, and healthspan extension, with similar Series A–C entry points.
• Apollo Ventures: Venture fund dedicated exclusively to aging and longevity research, founding and seeding biotechs targeting age-related disease. Direct peer given shared focus on longevity science and comparable stage/size to Korify's biotech allocations.
• Longevity Vision Fund: Early-to-growth stage fund investing in companies extending human longevity and healthspan, with strong overlap to Korify's mental health and regenerative medicine portfolio. Highly comparable in stage, theme, and biotech concentration.
• Maximon (Longevity Investors): Swiss-based longevity-focused investor building and scaling companies targeting aging, mental health, and regenerative medicine. Closely comparable European peer with overlapping themes and similar Series A–C deployment strategy.
• Pureos Bioventures: Swiss venture firm exclusively focused on next-generation drug development and biotech platform companies. Highly comparable in stage, European domicile, and biotech-only mandate to Korify's investment approach.

Regional players

• Alpha Cognition: Specialized biotech investor/operator focused on neurodegenerative and cognitive indications. Adjacent in mental health / neuroscience thesis to Korify's mental-health focus area, with overlapping therapeutic modalities but operating from a different angle.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/korify-capital

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments23 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Korify Capital